LISCure Biosciences Initiates Global Phase 2 Trial of LB-P8 in Primary Sclerosing Cholangitis

 LISCure Biosciences ("LISCure"), a clinical-stage biopharmaceutical company, announced the initiation of patient dosing in a global Phase 2 cl...

November 11, 2025 | Tuesday | News
Vascarta and CUNY Report Preclinical Breakthrough Demonstrating STO-1 Selectively Eliminates Glioblastoma Cells

Vascarta Inc., a healthspan focused, clinical stage biopharmaceutical company advancing safe, patient friendly therapies for pain, inflammation, and, in ...

November 11, 2025 | Tuesday | News
SanegeneBio and Eli Lilly Announce Global Collaboration on RNAi Therapies for Metabolic Diseases

  SanegeneBio, a clinical-stage biotechnology company developing innovative RNAi therapeutics, today announced a global research and licensing collab...

November 10, 2025 | Monday | News
Dupixent Delivers First Positive Phase 3 Results in Allergic Fungal Rhinosinusitis

Phase 3 data to be presented at ACAAI demonstrate Dupixent significantly reduced key nasal signs and symptoms including sinus opacification, nasal cong...

November 10, 2025 | Monday | News
Aceso and Samsung Partner to Advance Digital Transformation in Hospital Communication and Patient Care

-Aceso Interactive, Inc., a leading provider of patient engagement and healthcare communication technology, is pleased to announce a strategic partnershi...

November 07, 2025 | Friday | News
Clearmind Medicine Files Patent in South Korea for MEAI in Depression Treatment

Patent expands MEAI’s global intellectual property protection as Clearmind advances clinical development and commercialization plans Clearmind Med...

November 06, 2025 | Thursday | News
Jupiter Neurosciences Receives FDA IND Clearance to Initiate Phase 2a Trial of JOTROL™ in Parkinson’s Disease

Jupiter Neurosciences, Inc. (NASDAQ:JUNS), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based therapeutic pla...

November 06, 2025 | Thursday | News
INOVIO Completes BLA Submission for INO-3107, a DNA Immunotherapy for Recurrent Respiratory Papillomatosis

Recurrent respiratory papillomatosis (RRP) is a rare HPV-related disease of the respiratory tract with significant unmet need INO-3107 previously rece...

November 04, 2025 | Tuesday | News
Virax Biolabs Completes Full UK Recruitment for ViraxImmune™ Clinical Study on Long COVID and Related Syndromes

Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses t...

November 04, 2025 | Tuesday | News
NeuroKaire and Compass Pathways Partner to Advance AI-Driven Insights Into Psychedelic Therapies for Mental Health

Collaboration will leverage AI-powered neural analysis and Compass' expertise in psychedelic drug development to advance new therapies for mental health ...

November 03, 2025 | Monday | News
bioAffinity Technologies Secures Australian Patent Expanding Global Lung Health Portfolio

Australian patent strengthens global patent portfolio -bioAffinity Technologies, Inc. a biotechnology company advancing early-stage diagnostic...

October 30, 2025 | Thursday | News
Zag Bio Launches with $80 Million Financing to Pioneer Thymus-Targeted Therapies for Autoimmune Diseases

Discovery and development of the first systemic therapeutics to deliver self-antigens directly to the thymus to harness the body’s natural mechanis...

October 29, 2025 | Wednesday | News
GSK and Empirico Enter Exclusive Licensing Agreement for Novel siRNA Candidate EMP-012 in COPD

siRNA candidate EMP-012 in phase I for treatment of COPD EMP-012 targets a distinct inflammatory pathway with enhanced potency and longer dose int...

October 29, 2025 | Wednesday | News
Catalent Introduces New Corporate Brand to Champion “Missions That Matter” Across Global Healthcare

Reflects Catalent’s unparalleled service and best-in-class capabilities across the pharmaceutical, biotech and consumer health categories Rein...

October 29, 2025 | Wednesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close